Ista Pharmaceuticals Inc.
- Share via
The Irvine developer of products to treat eye diseases said it lost $5.2 million, or 33 cents a share, for the first quarter, compared with a pro forma net loss of $4.6 million a year earlier. No revenue was recorded for the company, which went public in August.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
